Ono Pharmaceutical, Bristol-Myers Squibb Company and Kyowa Hakko Kirin have entered into a clinical trial collaboration agreement to conduct a Phase 1 combination study Read the full story

The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story

Activiomics has extended its Contract Research Agreement with Japanese pharmaceutical company Kyowa Hakko Kirin by entering into a new pharma alliances research programme Read the full story

Ultragenyx Pharmaceutical has entered into pharma deals with Kyowa Hakko Kirin, to develop and commercialize KRN23. Read the full story

Kyowa Hakko Kirin, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years Read the full story

Ezose Sciences has entered into a biotech partnering deal with Kyowa Hakko Kirin, a big pharma company, to collaborate on glycomics studies using Ezose’s proprietary GlycanMap technology platform Read the full story

NovAliX has entered into a pharma alliances agreement, for development of fragment-based drug discovery, with bigpharma Kyowa Hakko Kirin Read the full story

Anchor Therapeutics has entered into a collaborative pharma partners agreement with Kyowa Hakko Kirin to utilize Anchor’s proprietary pepducin technology to advance KHK’s internal G protein-coupled receptor drug discovery portfolio.

Read the full story

This report provides all the information you require to better understand Kyowa Hakko Kirin and its partnering interests and activities over the past seven years.  Read the full story

Agreement with Kyowa Hakko Kirin providing Lundbeck with exclusive rights to develop and commercialise the adenosine A2a antagonist KW-6356. Read the full story